The CTLA-4, PD-1 track is crowded, and the development of the next generation of tumor immunotherapy is a new target for drug companies
The annual sales volume of Yuyue oxygen concentrator is the first in the world to exceed 1 million units
NEUROLOGY: White matter hyperintensity volume correlates with cognition 1 year after stroke
Yifang Bio's new KRAS G12C inhibitor achieved positive results in Phase 1 clinical trials
Notice of Liaoning Provincial Market Supervision and Administration Bureau on Food Safety Sampling Information (Issue 1, 2022)
Guangzhou Petrochemical continues to optimize and improve the purity of butene-1 products
The 12th anniversary of Zhenhai Refinery's 12th anniversary of the high-efficiency operation of No. 1 ethylene produced 12.85 million tons of ethylene
Announcement of Dalian Market Supervision and Administration Bureau on the Release of 370 Batches of Food Safety Sampling Results (No. 1, 2022)
Over 1 billion contrast agents!
Scientists discover anti-HIV-1 antibody treatment suppresses viral infection
The next round of competition for domestic PD-1 is shifting to overseas markets
First completed the administration of the first subject of the Phase I clinical trial for the oral preparation of GLP-1 polypeptide XW004
Pemetrexed: Folic acid and VB12 applied 1 week in advance or at the same time?
One picture to understand 13 PD-1/PD-L1 drugs approved in China
Diabetologia: Early and late histological confirmation of celiac disease in children with new-onset type 1 diabetes
Vietnam's monthly export of aquatic products reaches 1 billion US dollars
Uric acid less than 1 μmol/L?
"Cold" tumor becomes "hot" Oncolytic virus/CAR-T combination therapy Phase 1 clinical trial is about to start
with pembrolizumab in patients with advanced melanoma resistant to PD-1 immunotherapy
NICE recommends Koselugo for neurofibromatosis type 1